B. Riley Has Positive Estimate for Vaxart Q1 Earnings

Vaxart, Inc. (NASDAQ:VXRT) – Stock analysts at B. Riley increased their Q1 2025 earnings per share estimates for shares of Vaxart in a research note issued on Wednesday, March 26th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will earn ($0.07) per share for the quarter, up from their previous estimate of ($0.09). B. Riley has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Vaxart’s current full-year earnings is ($0.39) per share. B. Riley also issued estimates for Vaxart’s Q2 2025 earnings at ($0.08) EPS and Q3 2025 earnings at ($0.07) EPS.

Vaxart Stock Down 8.5 %

VXRT stock opened at $0.37 on Monday. Vaxart has a twelve month low of $0.37 and a twelve month high of $1.30. The stock has a market cap of $84.91 million, a P/E ratio of -0.91 and a beta of 1.69. The business’s 50-day moving average price is $0.60 and its 200-day moving average price is $0.68.

Vaxart (NASDAQ:VXRT) last posted its earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. The business had revenue of $15.19 million during the quarter, compared to the consensus estimate of $15.68 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%.

Hedge Funds Weigh In On Vaxart

A number of institutional investors and hedge funds have recently made changes to their positions in VXRT. Graham Capital Management L.P. lifted its position in Vaxart by 155.8% in the fourth quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company’s stock worth $35,000 after buying an additional 32,482 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in Vaxart by 140.9% during the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 35,213 shares during the last quarter. Invesco Ltd. raised its stake in shares of Vaxart by 48.6% in the fourth quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 24,803 shares during the period. XTX Topco Ltd lifted its holdings in shares of Vaxart by 869.3% in the 3rd quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock worth $116,000 after acquiring an additional 122,387 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 17,942 shares during the period. 18.05% of the stock is owned by hedge funds and other institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.